News

Portrai in media

Latest news

Meet Portrai, a Seoul startup mapping the human body for drug discovery

signalsventures
May 31, 2026

Every year, the pharmaceutical industry spends billions searching for cures. Most of it vanishes. According to McKinsey, the attrition-adjusted cost to develop a single drug asset is now estimated at up to $2.8 billion, and still, only about 13% of assets that enter Phase 1 trials ever make it to launch.

Beyond the Main Stage: A Showcase of the Next Wave of Korean Biotech Innovation at JPM Week 2026

geneonline
January 15, 2026

As the global biomedical industry converges in San Francisco for the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), South Korea has firmly established itself as a dominant force in the Asia-Pacific biotech landscape. While industry giants like Samsung Biologics and Celltrion commanded attention on the Main Track at the Westin St. Francis, a dynamic wave of innovation was unfolding just blocks away.

Artificial Intelligence in Radiation Protection of Patients: Diagnostic and therapeutic nuclear medicine

IAEA
November 25, 2025

As artificial intelligence (AI) continues to revolutionize healthcare, its potential to enhance patient safety and improve radiation protection practices is becoming increasingly evident. This webinar series aims to explore how AI-driven tools and technologies can support and advance the safe and effective use of radiation in medical settings. Tailored for a broad audience of healthcare professionals — including clinicians, radiologists, radiation oncologists, nuclear medicine physicians, technologists, medical physicists, hospital administrators and regulators — each session will feature expert led presentations followed by a live discussion. Participants can deepen their understanding and exchange ideas with leading professionals in the field.

Portrai, BL Melanis win Amgen–KHIDI Golden Ticket for 2025 biotech innovation

Korea Biomedical Review
November 13, 2025

Amgen Korea and the Korea Health Industry Development Institute (KHIDI) on Thursday announced two biotech start-ups — Portrai and BL Melanis — as the winners of the 2025 Golden Ticket, a global open innovation initiative by Amgen to identify promising biotech ventures and support their global growth. 출처 : KBR(https://www.koreabiomed.com)

Celltrion signs joint research deal with Portrai to discover cancer drug targets

ChosunBiz
October 29, 2025

Celltrion said on the 29th that it signed a joint research agreement with domestic artificial intelligence (AI) new drug developer Portrai to search for new drug targets using spatial transcriptomics and AI technology.

[Diplomacy Journal] Korea Startup Forum and the British Embassy jointly hold IR Day

Diplomacy Journal
July 17, 2025

The Korea Startup Forum (KOSFO) announced on July 17 that it successfully held the “KSF IR Day,” a practical IR program supporting promising domestic deep tech startup

Pick of the posters: AACR 2024

BioTechniques
April 25, 2024

At AACR 2024, we explored the poster hall to pick out the posters that would interest the BioTechniques reader and those we found delivered the most interesting or surprising findings. Get our selections below and let us know your thoughts on our Pick of the posters. Contents: pyVIPER: a fast and scalable toolkit for the […]

South Korean Biotech Company Portrai Inc. Adopts Infortrend Storage to Enable AI Data Analysis for Pharmaceutical Drug Development

PR Newswire
September 12, 2023

/PRNewswire/ -- Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage manufacturer, provided South Korean biotech company Portrai...

We innovate the process of developing new drugs
beyond the limits of human cognition, and deliver safer
and more effective new drugs to humanity.

Contact us

Portrai Inc.
1 Broadway, Cambridge, MA 02142
Phone: +82-2-766-2377
Email: contact@portrai.io
CEO: Daeseung Lee
Business Registration Number: 638-87-02032
Mail-Order Business Report Number: 2023-Seoul-Jongno-0783

Follow us on social media
© 2025 Portrai Inc. All rights reserved.